Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2007-11-27
2007-11-27
Habte, Kahsay (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C544S235000
Reexamination Certificate
active
10913307
ABSTRACT:
Compounds, pharmaceutical compositions and methods that are useful in the treatment or prevention of metabolic and cell proliferative diseases or conditions are provided herein. In particular, the invention provides compounds which modulate the activity of proteins involved in lipid metabolism and cell proliferation.
REFERENCES:
patent: 4166452 (1979-09-01), Generales, Jr.
patent: 4256108 (1981-03-01), Theeuwes
patent: 4265874 (1981-05-01), Bonsen et al.
patent: 6069143 (2000-05-01), Ali et al.
patent: 6472389 (2002-10-01), Ohtani et al.
patent: 6512099 (2003-01-01), Omura et al.
patent: 2004/0209871 (2004-10-01), Fox et al.
patent: 1 431 267 (2004-06-01), None
patent: 05-213985 (1993-08-01), None
patent: 2002-284741 (2002-10-01), None
patent: 2004-067635 (2004-03-01), None
patent: 2003-045230 (2003-06-01), None
patent: WO 01/32632 (2001-05-01), None
patent: WO 01/32632 (2001-05-01), None
patent: WO 03/016254 (2003-02-01), None
patent: WO 03/018536 (2003-03-01), None
patent: WO 2005/072740 (2005-08-01), None
Cecil Textbook of Medicine, edited by Bennet, J.C., and Plum F., 20th edition,vol. 1, 1004-1010, 1996.
Chen et al., Trends in Cardiovascular Medicine 10: 188-192, 2000.
Chen et al. Arterioscler. Vasc. Biol. 25 (3): 482-486, 2005 (abstract two pages).
Wolff Manfred E. “Burger's Medicinal Chemistry, 5ed, Part 1”, John Wiley & Sons, 1995, pp. 975-977.
Banker, G.S. et al, “Modern Pharmaceutices, 3ed.”, Marcel Dekker, New York. 1996, pp. 451 and 596.
Moore et al. J. Org. Chem., vol. 37, No. 24, 1972.
Bagdade,Diabetes Reviews, 5(4): 392-409 (1997).
Bast et al., “Imunostimulants”, Chapter 60, Section 16, pp. 790-799, inCancer Medicine, 5thed: (Hamilton, Ontario, CA: B.C. Decker, 2000).
Berge et al.,Journal of Pharmaceutical Sciences, 66(1): 1-19 (Jan. 1977).
Buhman et al.,Journal of Biological Chemistry, 277(28): 25474-25479 (Jul. 12, 2002).
Cases et al.,Journal of Biological Chemistry, 276(42): 38870-38876 (Oct. 19, 2001).
Cases et al.,Proc. Natl. Acad. Sci. USA, 95: 13018-13023 (Oct. 1998).
Chen et al.,Diabetes Reviews, 5(4): 331-342 (1997).
Chen et al.,Journal of Clinical Investigation, 109(8): 1049-1055 (Apr. 2002).
Chen et al.,Trends Cardiovasc. Med., 10(5): 188-192 (2000).
Chiasson et al.,Annals of Internal Medicine, 121(12): 928-935 (Dec. 15, 1994).
Clemmons,Diabetes Reviews, 5(4): 353-364 (1997).
Coniff et al.,American Journal of Medicine, 98: 443-451 (May 1995).
Coniff et al.,Clinical Therapeutics 19(1): 16-26 (1997).
Dean et al.,Journal of Organic Chemistry, 58: 7916-7917 (1993).
Farese et al.,Curr. Opin. Lipidol., 11:229-234 (2000).
Garg et al.,Diabetes Reviews, 5(4): 425-433 (1997).
Haffner,Diabetes Care, 21(1): 160-178 (Jan. 1998).
Hsueh et al.,Diabetes Reviews, 5(4): 343-352 (1997).
Iwamoto et al.,Diabetic Medicine, 13(4): 365-370 (Apr. 1996).
Jokl et al.,Diabetes Reviews, 5(4): 316-330 (1997).
Kwiterovich,The American Journal of Cardiology, 82(12A): 3U-17U (Dec. 17, 1998).
Laakso et al.,Diabetes Reviews, 5(4): 294-315 (1997).
Lewis et al.,Endocrine Reviews, 23(2): 201-229 (Apr. 2002).
Lopes-Virella et al.,Diabetes Reviews, 5(4): 410-424 (1997).
Lyons et al.,Diabetes Reviews, 5(4): 365-391 (1997).
Mahler et al.,Journal of Clinical Endocrinology&Metabolism, 84(4): 1165-1171 (Apr. 1999).
Malloy et al., “Chapter 4: A Risk Factor for Atherosclerosis: Triglyceride-rich Lipoproteins,”Advances in Internal Medicine, 47: 111-136 (Mosby, Inc., 2001).
March,Advanced Organic Chemistry, 4thed: 1091-1092 (New York: John Wiley & Sons, 1992).
Newcomb et al.,Journal of Organic Chemistry, 45: 1707-1708 (1980).
Oelkers et al.,Journal of Biological Chemistry, 273(41): 26765-26771 (Oct. 9, 1998).
Purnell et al.,Diabetes Reviews, 5(4): 434-444 (1997).
Samaritoni,Organic Preparations and Procedures International(OPPI), 20(2): 117-121 (Apr. 1988).
Smith et al.,Nature Genetics, 25: 87-90 (May 2000).
Turner et al., “Insulin resistance, impaired glucose tolerance and non-insulin-dependent diabetes, pathologic mechanisms and treatment: Current status and therapeutic possibilities,”Progress in Drug Research, 51: 33-94 (Basel, Switzerland: Birkhäuser Verlag, 1998).
United Kingdom Prospective Diabetes Study (UKPDS) Group,Diabetes Care, 21(1): 87-92 (Jan. 1998).
Wermuth (ed.), “Molecular Variations Based on Isosteric Replacements,”The Practice of Medicinal Chemistry, 13: 203-237 (London: Academic Press Limited, 1996).
Barone,Journal of Medicinal Chemistry, 6: 39-42 (Jan. 1963).
Chen et al.,Diabetes, 51: 3189-3195 (2002).
Chen et al.,Journal of Clinical Investigation, 111: 1715-1722 (2003).
Chen et al.,Diabetes, 54(12): 3379-3386 (2005).
Chung et al.,Planta Med., 70: 256-258 (2004).
Gaziano et al.,Circulation, 96: 2520-2525 (1997).
Kim et al.,J. Medicinal Chemistry, 17(3): 369-371 (1974).
Ko et al.,Archives of Pharmacal Research, 25(4): 446-448 (2002).
Landauer et al.,Journal of Chemical Society: 3721-3722 (1953).
Lee et al.,Planta Med, 70: 197-200 (2004).
Nahm et al.,Tetrahedron Letters, 22(39): 3815-3818 (1981).
Oikawa, “Medicine for 21st Century: New Perspectives for Diagnosis and Treatment of Arteriosclerosis,” 51-56 (2000).
Robbins et al., “Blood Vessels” inPathologic Basis of Disease, 6thed., W. B. Saunders Company: Philadelphia, 498-510 (1999).
Rustan et al.,Journal of Lipid Research, 29: 1417-1426 (1988).
Subauste et al.,Curr. Drug Targets Immune Endocr. Metabol. Disord., 3(4): 263-270 (2003).
Tomoda et al.,The Journal of Antibiotics, 48(9): 937-941 (Sep. 1995).
Tomoda et al.,The Journal of Antibiotics, 52(8): 689-694 (Aug. 1999).
Turkish et al.,J. Biol. Chem., 280(15): 14755-14764 (2005).
Vaziri et al.,Kidney Int., 66(1): 262-267 (2004).
Yu et al.,Hepatology, 42(2): 362-371 (2005).
Fox Brian M.
Iio Kiyosei
Inaba Takashi
Kayser Frank
Li Kexue
Habte Kahsay
Japan Tobacco Inc.
Leydig , Voit & Mayer, Ltd.
LandOfFree
Pyrrolo[1,2- b ]pyridazine derivatives does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Pyrrolo[1,2- b ]pyridazine derivatives, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Pyrrolo[1,2- b ]pyridazine derivatives will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3858569